Clinical trials show GLP-1 receptor agonists may have neuroprotective effects in Alzheimer's and Parkinson's, but evidence remains limited.
4 databasesComprehensive literature search across Web of Science, Medline, Embase, and ClinicalTrials.gov
What the researchers found
Human clinical trials show early promise for GLP-1 receptor agonists in neurodegenerative diseases, supported by strong preclinical evidence of neuroprotection.
Why it matters
Effective disease-modifying treatments for Alzheimer's and Parkinson's remain elusive — repurposing GLP-1 drugs could accelerate progress.
The numbers in context
11 clinical trials reviewed. Liraglutide improved brain glucose metabolism and transport in AD. Exenatide showed motor improvements in PD. Preclinical data support anti-inflammatory, antioxidant, and anti-apoptotic effects.
How the study worked
Narrative literature review analyzing human clinical trials from Web of Science, Medline, Embase, and ClinicalTrials.gov.
Who was studied
Patients with AD or PD
What this study cannot tell us
Limited number of completed human trials. Narrative review format — not a systematic review with meta-analysis.
How to read the evidence
Literature review of clinical trials — evidence is promising but early-stage, with small trial sizes and limited follow-up.
When this study was published
Published in 2025, capturing the latest clinical trial landscape for GLP-1 drugs in neurodegeneration.
The bigger picture
If GLP-1 drugs prove neuroprotective in large trials, millions of diabetes patients already taking them may be receiving an unintended brain health benefit.
Questions still open
- Which GLP-1 drug is most promising for neurodegenerative disease?
- Are the neuroprotective benefits dose-dependent?
Common questions
Could GLP-1 drugs prevent dementia?
How might GLP-1 drugs protect the brain?
Read the original research
The Role of Glucagon-like Peptide-1 Receptor Agonists in Alzheimer's and Parkinson's Disease: A Literature Review of Clinical Trials.
Life (Basel, Switzerland), 15(12)
Citation
Pilśniak, Joanna; Węgrzynek-Gallina, Julia; Bednarczyk, Błażej; Buczek, Aleksandra; Pilśniak, Aleksandra; Chmiela, Tomasz; Jarosińska, Agnieszka; Siuda, Joanna; Holecki, Michał. (2025). The Role of Glucagon-like Peptide-1 Receptor Agonists in Alzheimer's and Parkinson's Disease: A Literature Review of Clinical Trials.. Life (Basel, Switzerland), 15(12). https://doi.org/10.3390/life15121893